Given the limitations of existing treatments, CRISPR gene-editing technology has emerged as a promising strategy to precisely target the molecular pathways underlying IS pathophysiology.
First-pass extracted concept
CRISPR-based therapy for ischemic stroke
Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
The review states that preclinical advances in CRISPR-based ischemic stroke therapy are substantial but are primarily in rodent models.
Quoted textsource-backed
Despite persistent challenges in targeted and safe delivery, substantial preclinical advances, primarily in rodent models, underscore the potential for CRISPR-based therapies to transform future stroke treatment.
Targeted and safe delivery remains a persistent challenge for CRISPR-based therapy in ischemic stroke.
Quoted textsource-backed
Despite persistent challenges in targeted and safe delivery, substantial preclinical advances, primarily in rodent models, underscore the potential for CRISPR-based therapies to transform future stroke treatment.
The review considers CRISPR modulation of cell communication, organelle transfer, and mitochondrial mutation correction as potential neuroprotective mechanisms in ischemic stroke.
Quoted textsource-backed
The use of CRISPR to modulate cell communication and organelle transfer and correct mitochondrial mutations has also been considered a neuroprotective mechanism.
CRISPR gene-editing technology is presented as a promising strategy to precisely target molecular pathways underlying ischemic stroke pathophysiology.
Quoted textsource-backed
CRISPR gene-editing technology has emerged as a promising strategy to precisely target the molecular pathways underlying IS pathophysiology.